We are live on ! Find out more
EPIX

ESSA Pharma
EPIX

Delisted

EPIX was delisted on the 8th of October, 2025.

Back to rankings

39 hedge funds and large institutions have $89.8M invested in ESSA Pharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

5% more funds holding

Funds holding: 37 → 39 (+2)

0.36% more ownership

Funds ownership: 75.06% → 75.41% (+0.36%)

9% less capital invested

Capital invested by funds: $98.3M → $89.8M (-$8.5M)

10% less call options, than puts

Call options by funds: $96K | Put options by funds: $107K

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
39
Holders Change
+2
Holders Change %
+5.41%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
10
Closed
3
Calls
$96K
Puts
$107K
Net Calls
-$11K
Net Calls Change
-$83K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$2.24M
2
RSCM
Rock Springs Capital Management
Maryland
+$406K
3
SCM
Soleus Capital Management
Connecticut
+$167K
4
Millennium Management
Millennium Management
New York
+$146K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$145K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$810K
2
ABG
Ally Bridge Group
New York
-$703K
3
DCM
Driehaus Capital Management
Illinois
-$693K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$415K
5
CIBC World Market
CIBC World Market
Ontario, Canada
-$141K

EPIX Hedge Fund Activity: Q2 2023 in Review

39 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2023, worth a combined $89.8M — down 8.7% from $98.3M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EPIX positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $2.24M. The largest seller was OrbiMed, cutting an estimated $810K.

  • 39 institutional investors held ESSA Pharma (EPIX) as of Q2 2023, up from 37 in Q1 2023.
  • Funds reported $89.8M of ESSA Pharma stock for Q2 2023, down 8.7% quarter-over-quarter.
  • 5 funds opened new ESSA Pharma positions in Q2 2023 and 3 closed out, a net change of +2 holders.
  • The largest ESSA Pharma buyer in Q2 2023 was Morgan Stanley, an estimated $2.24M added.
  • The largest ESSA Pharma seller in Q2 2023 was OrbiMed, an estimated $810K sold.

Based on aggregated 13F filings for Q2 2023.